These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 22104158)
21. [Reduction of Treatment Duration in Periprosthetic Infection with a Fast-Track Concept Is Economically Not Feasible]. Lieb E; Hanstein T; Schuerings M; Trampuz A; Perka C Z Orthop Unfall; 2015 Dec; 153(6):618-23. PubMed ID: 26468925 [TBL] [Abstract][Full Text] [Related]
22. Chemotherapy-induced febrile neutropenia (FN): healthcare resource utilization (HCRU) and costs in commercially insured patients in the US. Flanigan JA; Yasuda M; Chen CC; Li EC Support Care Cancer; 2024 May; 32(6):373. PubMed ID: 38777864 [TBL] [Abstract][Full Text] [Related]
23. Financing in knee arthroplasty: a benchmarking analysis. Effenberger H; Rehart S; Zumstein MD; Schuh A Arch Orthop Trauma Surg; 2008 Dec; 128(12):1349-56. PubMed ID: 18309508 [TBL] [Abstract][Full Text] [Related]
24. Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy. Chia VM; Page JH; Rodriguez R; Yang SJ; Huynh J; Chao C Breast Cancer Res Treat; 2013 Apr; 138(2):621-31. PubMed ID: 23468242 [TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom. Whyte S; Cooper KL; Stevenson MD; Madan J; Akehurst R Value Health; 2011 Jun; 14(4):465-74. PubMed ID: 21669371 [TBL] [Abstract][Full Text] [Related]
27. Treatment of febrile neutropenia is expensive: prevention is the answer. Klastersky JA; Paesmans M Onkologie; 2011; 34(5):226-8. PubMed ID: 21577026 [No Abstract] [Full Text] [Related]
28. [How does the German DRG system differentiate and reimburse vitreoretinal surgery in diabetic patients?]. Krause M; Goldschmidt AJ; Berg M; Kropf S; Sachs A; Gatzioufas Z; Brückner K; Seitz B Klin Monbl Augenheilkd; 2008 Oct; 225(10):880-7. PubMed ID: 18951309 [TBL] [Abstract][Full Text] [Related]
29. Prospective multi-center study for quantification of chemotherapies and CTX-related direct medication costs avoided by use of biomarkers uPA and PAI-1 in primary breast cancer. Jacobs VR; Augustin D; Wischnik A; Kiechle M; Höss C; Steinkohl O; Rack B; Kapitza T; Krase P Breast; 2013 Aug; 22(4):436-43. PubMed ID: 23643802 [TBL] [Abstract][Full Text] [Related]
30. The possible impact of the German DRGs reimbursement system on end-of-life decision making in a surgical intensive care unit. Stachura P; Oberender P; Bundscherer AC; Wiese CH Wien Klin Wochenschr; 2015 Feb; 127(3-4):109-15. PubMed ID: 25622109 [TBL] [Abstract][Full Text] [Related]
31. Economic comparison of home-care-based versus hospital-based treatment of chemotherapy-induced febrile neutropenia in children. Raisch DW; Holdsworth MT; Winter SS; Hutter JJ; Graham ML Value Health; 2003; 6(2):158-66. PubMed ID: 12641866 [TBL] [Abstract][Full Text] [Related]
32. [Comparison of hand surgery in the German and Italian DRG systems]. Lotter O; Dolderer J; Stahl S; Atzei A; Haerle M; Schaller HE Gesundheitswesen; 2011 Dec; 73(12):843-8. PubMed ID: 20886418 [TBL] [Abstract][Full Text] [Related]
33. [DRG reimbursement for multiple trauma patients -- a comparison with the comprehensive hospital costs using the German trauma registry]. Grotz M; Schwermann T; Lefering R; Ruchholtz S; Graf v d Schulenburg JM; Krettek C; Pape HC Unfallchirurg; 2004 Jan; 107(1):68-75. PubMed ID: 14749855 [TBL] [Abstract][Full Text] [Related]
34. Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre. Schelenz S; Giles D; Abdallah S Ann Oncol; 2012 Jul; 23(7):1889-93. PubMed ID: 22048152 [TBL] [Abstract][Full Text] [Related]
35. [Costs for acute, stationary treatment of polytrauma patients]. Schmelz A; Ziegler D; Beck A; Kinzl L; Gebhard F Unfallchirurg; 2002 Nov; 105(11):1043-8. PubMed ID: 12402131 [TBL] [Abstract][Full Text] [Related]
36. [Does the hospital cost of care differ for inflammatory bowel disease patients with or without gastrointestinal infections? A case-control study]. Schmidt C; Köhler F; Kräplin T; Hartmann M; Lerch MM; Stallmach A Z Gastroenterol; 2014 Jul; 52(7):643-8. PubMed ID: 25026005 [TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of intensive adjuvant chemotherapy for high-risk breast cancer: is tailored and dose-escalated chemotherapy with growth factor support (GFS) more costly and less effective than marrow-supported high-dose chemotherapy - results from a randomized study. Kellokumpu-Lehtinen P; Bergh J; Salminen E; Wiklund T; Lehtinen S; Aronen P; Sintonen H Acta Oncol; 2007; 46(2):146-52. PubMed ID: 17453362 [TBL] [Abstract][Full Text] [Related]
38. Childbirth and Diagnosis Related Groups (DRGs): patient classification and hospital reimbursement in 11 European countries. Bellanger MM; Quentin W; Tan SS Eur J Obstet Gynecol Reprod Biol; 2013 May; 168(1):12-9. PubMed ID: 23375210 [TBL] [Abstract][Full Text] [Related]
39. Neutropenic infections add significant costs to palliative chemotherapy in breast cancer. Korpela J; Salminen E Anticancer Res; 2002; 22(2B):1337-40. PubMed ID: 12168947 [TBL] [Abstract][Full Text] [Related]
40. [Can Topical Negative Pressure Therapy be Performed as a Cost-Effective General Surgery Procedure in the German DRG System?]. Hirche Z; Xiong L; Hirche C; Willis S Zentralbl Chir; 2016 Apr; 141(2):197-203. PubMed ID: 26135611 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]